Semaglutide works for the majority who try it, but it doesnt work the same way for everyone
276 Recently, in a study utilizing multimodal MRI data, patients with MDD were successfully distinguished from healthy controls by radiomics analysis
Clinically, GLP-1-based therapies offer the additional advantage of established cardiovascular protection and renal benefits, making them particularly attractive for the large proportion of MASLD patients with comorbid cardiovascular disease or type 2 diabetes
It does not prevent gas formation
The product has been promoted on social networks such as TikTok and the internet for its effects in reducing fat deposits on the face and certain parts of the body
The growing popularity of GLP-1 receptor agonists, especially semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), both of which are FDA-approved for type 2 diabetes and/or obesity and, has been accompanied by considerable social media attention and discussion, from which thorough analyses of user-generated data have emerged highlighting reductions in alcohol-seeking motivation, decreased drinking behavior, and altered subjective responses to alcohol (Arillotta et al
/i.s3.glbimg.com/v1/AUTH_da025474c0c44edd99332dddb09cabe8/internal_photos/bs/2023/I/w/vAkiMJS7KmoxJky6P50g/design-sem-nome-7-.png)
